Drug Type Synthetic peptide |
Synonyms NAFB-001, P-144, PEPTIDE 144 + [1] |
Target |
Mechanism TGF-β1 inhibitors(Transforming growth factor beta 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC68H109N17O22S2 |
InChIKeyIUYPEUHIWDMJLM-SWHDLQTQSA-N |
CAS Registry272105-42-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fibrosis | Phase 2 | DE | 01 Jul 2008 | |
Fibrosis | Phase 2 | HU | 01 Jul 2008 | |
Fibrosis | Phase 2 | IT | 01 Jul 2008 | |
Fibrosis | Phase 2 | PL | 01 Jul 2008 | |
Fibrosis | Phase 2 | ES | 01 Jul 2008 | |
Fibrosis | Phase 2 | GB | 01 Jul 2008 | |
Scleroderma, Systemic | Phase 2 | DE | 01 Jul 2008 | |
Scleroderma, Systemic | Phase 2 | HU | 01 Jul 2008 | |
Scleroderma, Systemic | Phase 2 | IT | 01 Jul 2008 | |
Scleroderma, Systemic | Phase 2 | PL | 01 Jul 2008 |